Introduction: The discovery and development of new treatments for Alzheimer's disease (AD) requires a profound mechanistic understanding of the disease. Here, we propose a model-driven approach supporting the systematic identification of putative disease mechanisms.
Introduction
Difficulties with the diagnosis of Alzheimer's disease (AD) and the absence of disease-modifying treatments for AD remain among the great challenges in biomedicine that need to be addressed in the 21st century. Recent disappointing results of Alzheimer's treatment trials reaffirm that pathogenic mechanisms underlying dementia are more complex than previously thought [1] . Given the obvious complexity of the AD pathology, an important question that arises is whether current knowledge provides a way forward to better understand the underlying pathological pathways.
It has been long hypothesized that the deposition of amyloid-beta peptide in the brain triggers a cascade of molecular events that consequently lead to AD dementia. The amyloid hypothesis represents the mainstream scientific opinion and knowledge on the cause and progression of AD, despite the growing skepticism surrounding this hypothesis [1] . The amyloid-beta protein also plays normal physiologic roles, for example, as protein hormones [2] . Given the amount of accumulated knowledge on both normal and abnormal function of amyloid, which remains scattered in the form of free text and representations in various pathway databases, in silico modeling methods provide a means of aggregating and presenting this information in a collated, computer-readable format. Major biological processes and pathways involved in the pathogenesis of AD have been collectively represented in the form of the AlzPathway map [3] . However, to be useful and supportive for drug and biomarker discovery efforts, such disease maps need to go beyond the pure representation of pathway information as cartoons, which suffer from missing biological entities (such as Single Nucleotide Polymorphisms [SNPs] ) and difficulties in relational representation. Unfortunately, current AD models do not capture the dynamic nature of the disease (e.g. staging) and because of the lack of time course gene expression data on AD in humans, these models do not permit to go beyond the simple overlay of expression snapshots obtained from post-mortem brains. Future modeling approaches should thus support the automatic reasoning of interlinked molecules and processes. We argue that a computer-processable disease model should be readily amenable to computational reasoning for disease mechanism discovery based on the identification of causeand-effect regulatory effects, thus linking upstream causal entities to downstream bioclinical effects. Furthermore, in the absence of healthy state models that represent normal cellular processes, any attempt to derive mechanistic interpretations of disease is inconclusive. Thus, disease mechanism discovery requires the conversion of descriptive knowledge into computer-processable cause-and-effect models and mechanistic interpretation should be addressed by the differential analysis of normal and abnormal processes.
We address these requirements by constructing two causeand-effect computer-processable models for pathophysiological processes associated with AD and their healthy state analogs based on the Biological Expression Language (BEL; http://www.openbel.org/). BEL integrates literature-derived "cause and effect" relationships into network models, which can be subjected to causal analysis using quantitative data such as gene expression. The models developed here not only represent a comprehensive view on the core established pathways involved in amyloid processing but also cover a broad spectrum of events that lead to clinical readouts often seen in AD patients, such as neuroinflammatory processes. Moreover, the healthy and disease state models provide a means for mechanistic differential analysis through which causal pathogenic pathways can be identified.
Methods

Data collection and human APP BEL model building
The scientific knowledge of physiological functions (normal) and pathological actions (diseased) of amyloid precursor protein (APP) processing were acquired from ADrelated articles, reviews, and databases. First, 37 pathway cartoons were collected from pathway databases (such as Kyoto Encyclopedia of Genes and Genomes [KEGG] (http://www.genome.jp/kegg/), Reactome (http://www. reactome.org/PathwayBrowser/), and BioCarta (http:// www.biocarta.com/genes/index.asp)). Second, using SCAIView [4] we retrieved a list of 4124 genes, reported to be linked to pathology of AD, of which the top 50 genes were selected based on their relevancy to the query. Documents tagged for these genes were manually filtered for normal (64 documents) and disease (295 documents) states. Relationships reported in these documents were encoded in BEL language v1.0 and used to build the APP BEL models. Furthermore, documents related to top 10 AD related genes were obtained from the AlzGene Database [5] . The APP BEL models were validated for correct syntax and compiled using the OpenBELFramework v2.0, omitting Phase III network augmentation. The models were visualized using Cytoscape and queried using the OpenBEL Knowledge Assembly Model (KAM) Navigator Cytoscape plug-in (https:// github.com/OpenBEL/Cytoscape-Plugins).
Comparison of the normal and disease state models
To identify differential pathways, which are specifically present in the disease state model, the two APP models were compared using the Cytoscape plug-in "advanced network analysis" [6] .
GSEA using MSig database
The "Compute Overlaps" tool available via MSigDB (http://www.broadinstitute.org/gsea/msigdb/help_annotatio ns.jsp#overlap) was used to identify enriched pathways in the BEL models and the AlzPathway map, using the canonical pathways collection of gene sets (MSig database v4.0 updated May 31, 2013) . This was used to identify the common canonical pathways between Normal and Disease state BEL models and to revalidate the specificity of models with AD context and to compare it with the existing AlzPathway model. Three canonical pathway data sets were used to compute overlaps; BioCarta, Reactome, and KEGG. Analysis was done using the entire gene list of both (normal and diseased) models and AlzPathway. From the BEL models, we have extracted all the genes/proteins/RNA names (referenced by HUGO Gene Nomenclature Committee [HGNC] namespace) and given as input for computing overlaps. For further analysis, we have selected the top ranked pathways by the number of genes with the highest P-value and FDR-q value by Gene Set Enrichment Analysis (GSEA) analysis. From the common pathways, the overlapping genes were identified for both disease and normal BEL models and identified how these pathways differentiate the normal and diseased states.
SNP analysis for comorbidity
Genetic variants (SNPs) for Alzheimer disease (AD) and genes of APP-related pathways were collected from PubMed and genome-wide association studies (GWAS) databases in which SNPs were identified for AD and genes of APP-related pathways. Using GWAS databases, more than 9000 SNPs for AD with the P-value threshold ,10 23 were collected. Of this, 96 SNPs associated with 47 genes were encoded in the APP-disease model. SNPs were prioritized according to their functional effect on the gene/protein in the disease context based on scores referring to the RegulomeDB database (http://regulome. stanford.edu/index) and experimental evidence for their position in a chromatin state was obtained from the ChroMoS web tool [7] .
Results
APP biology models representing normal versus disease processes in human brain
Following the workflow illustrated in Fig. 1 , 295 articles were found to contain essential information on APP processing under disease condition in human brain and were used to build the so-called "APP-Disease model"; similarly, 64 articles were used to construct the "APP-Normal model" representing the analogous normal processing of APP in neurons (Fig. 2) . This imbalance between the number of articles is reflecting the publication bias toward APP in the disease context as compared with reports on its normal biological role. Although we are aware of this bias, we aimed at the maximum coverage of causal and correlative statements that can be encoded in BEL. Consequently, the models we present here have grown way beyond this wellcharacterized APP pathophysiological endpoint and now include the vast majority of AD associated processes and pathways. As a result, the models encoded in BEL consist of 701 nodes for "APP-Normal" and 1314 nodes for "APPDisease". There are 920 BEL knowledge statements configuring the APP-Normal model and 2087 BEL statements supporting the APP-Disease model. The total numbers of interactions (edges) in normal and disease models are 1416 and 2935, respectively.
The APP BEL models (normal and disease) were compared with the previously published AlzPathway model in terms of information coverage [3] . A comparison among all three models is shown in Supplementary Table 1. To investigate functional similarities and differences in content, a comparative pathway analysis was performed with the AlzPathway model using pathway enrichment analysis (see Methods) with the canonical pathways in the MSig database [9] (Supplementary Table 2 ). The literature supporting the role of unique pathways of APP-Disease model indicates that these unique pathways form the core of hypotheses describing the pathology of AD (Supplementary Table 3) 
Differential analysis of APP-Normal and APPDisease models for identification of causal events
The differential model analysis aims to identify pathophysiological mechanisms underlying disease in comparison to the normal baseline function. We developed a strategy for differential model analysis that normalizes between the two models at the level of common, overlapping processes and pathways.
After the alignment of two APP models, we identified the disease-specific parts of the APP-Disease model by subtraction of the nodes and edges shared by both models. The resulting "delta" model was subjected to pathway enrichment analysis, which resulted in the identification of several pathways enriched in the portion of the model that is unique to disease, for example, the neurotrophin signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, and signaling by nerve growth factor (NGF). The identification of these pathways provides a starting point for the generation of mechanistic hypotheses. The integration of additional information from high-throughput data sources (e.g. GWAS data; gene expression data) and scientific literature not used to build the BEL model (e.g. patent literature) provide independent evidence for the relevance of a putative disease mechanism identified through differential model analysis.
Because the neurotrophin signaling pathway was among the top identified, disease-associated pathways, we investigated this pathway in more detail. In our BEL models, we identified four key regulators of the neurotrophin signaling cascade as described in the KEGG neurotrophin pathway, namely NTRK2 (neurotrophic tyrosine kinase receptor, type 2), BDNF (brain-derived neurotrophic factor), nerve growth factor receptor, and NGF. However, the differential model analysis reveals that the mode of interaction among these four proteins drastically differs between the normal and disease states. Accordingly, these proteins control two branches of the neurotrophin pathway, which regulate the balance between two possible biological outcomes, namely neuron survival versus apoptosis (Fig. 3) .
The neurotrophic protein BDNF and its receptor NTRK2 are involved in neuron differentiation and growth. In the normal state, ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquinating enzyme that controls BDNFmediated retrograde transport, activates BDNF, and increases the binding of BDNF to its receptor NTRK2, thereby promoting neuronal development and homeostasis. In contrast, under AD conditions, amyloid-beta prevents the binding of BDNF to NTRK2 receptor, thereby blocking BDNF-NTRK2 downstream signaling. This blockade leads to the repression of neuron survival, differentiation, and growth, so that abnormal APP processing and amyloidbeta production has been experimentally shown to attenuate BDNF-NTRK2 signaling [10] . UCHL1 activity is repressed by amyloid-beta, which in turn impairs BDNF-NTRK2-mediated downstream signaling, leading to diminished synaptic plasticity and neuronal survival [11] . Our BEL models also shed light on a second pathophysiology mechanism of two other proteins involved in neurotrophin signaling: NGFR and NGF. In the normal state, the NGF protein binds to NGFR resulting in NGFR polyubiquitination. Ubiquitinated NGFR binds to inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB) and activates nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1), which promotes neuronal cell survival [11] . In the disease state, amyloid beta peptides competitively bind to the NGFR and inhibit the binding of NGF, resulting in increased cell death [13, 14] .
An exhaustive search of patent and nonpatent literature for further evidence supporting the mechanism of competitive blocking of the NGF receptor through APP peptides revealed that although the literature supports the inhibition of BDNF signaling by APP and the induction of NGFR-mediated cell death by APP, separately, the embedding of the competitive binding of NGF and APP peptides in the context of the model shown in Fig. 3 brings these observations together as a novel, cohesive disease mechanism. Further supportive evidence comes from the patent literature [15] . Accordingly, the occurrence of a mutation from lysine to alanine at position 34 of the NGF amino acid sequence has been detected that results in binding mutant NGF molecule to NGFR with 50% lower affinity. Interestingly, the patent reports Fig. 1 . Schematic representation of the model construction and analysis workflow: Two amyloid precursor protein (APP) models were built using the scientific knowledge present in the scientific literature, databases, pathway cartoons, and genomic databases. The two models represent the normal neuron physiology and the diseased state physiology. The initial models have undergone an enrichment through Reverse Causal Reasoning (RCR) analysis [8] . Differential model comparison based on gene set enrichment led to the generation of two hypotheses, which were investigated further in silico and are supported by additional, independent evidence. a simultaneous occurrence of the amino acid sequence "lysine-glycine-alanine" in the amyloid peptide that provides a binding site for NGFR, thus creating a competitive binding capacity for the amyloid peptide.
Systematic aggregation of evidence in support of the amyloid-mediated neurotrophin switch hypothesis
The putative amyloid-mediated switch mechanism identified through differential model analysis of the neurotrophin signaling pathway is based on qualitative information. To further support the mechanism of action exerted by amyloid beta in the neurotrophin signaling pathway, we systematically harvested and screened independent pieces of evidence from experimental databases containing data sets on knockout mouse models and miRNAs. For four key regulators in the neurotrophin signaling pathway (BDNF, NGF, NGFR, and NTRK2), knockout mice were identified in the Mouse Genome Informatics database [12] and this provides supportive evidence for the proposed amyloid-switch mechanism (Supplementary Table 4) .
We also systematically investigated reports on miRNAs that regulate the genes in the neurotrophin pathway. Indeed, several miRNA studies provide supportive evidence for a key role of members of the neurotrophin pathway in early decision making on neuron survival [16, 17] (see Supplementary Table 5 ).
Biomarker-guided validation of the amyloidmediated neurotrophin switch hypothesis
Mentions of potential biomarkers in the literature can be used for biomarker-guided pathway analysis [18] . We therefore extracted mentions of potential biomarker functions of BDNF, NTRK2, NGF, and NGFR from the literature (Supplementary Table 6 ). Mapping these evidences for expressed biomarkers to the neurotrophin pathway clearly supports the amyloid-dependent switch mechanism hypothesis (Fig. 3) . The coordinated decrease in the levels of NGF and increased expression of NGFR protein, on one hand, and consistent decrease in levels of BDNF-NTRK2 complex, on the other hand, is aligned with our hypothesis and can be mechanistically explained by the model. In addition, the decreased expression of BDNF and NTRK2 in synergy with the inhibitory effect of amyloid beta on UCHL1 leads to "switching" the entire pathway from its normal state with neuroprotective effect to the disease state with a strong trend toward neuron apoptosis.
Inclusion of genome variation information in causal models
The addition of information on genetic variation to BEL models can support the generation of new hypotheses and analyze their mechanistic link to comorbidities of AD such as diabetes. The enrichment analysis of our models earlier indicated that insulin signaling pathway is among significantly enriched pathways connected to the APP processing (see Supplementary Table 2 ). Accumulated evidence suggests that type 2 diabetes mellitus (T2DM) is a strong risk factor for AD, as shown by Akomolafe (2006) [19] and patients treated with insulin were at highest risk of dementia [20] .
Consistent with these findings, analysis of APP-Normal and APP-Disease models revealed that some interactions in Table 7 ). Two of the three genes (CLU and STK11) could be integrated with prior knowledge to build a hypothesis (Fig. 4) .
Model-guided interpretation of genetic variation data by inferring chains of causation
The comorbidity model shown in Fig. 4 reveals the possible causative effects of genetic variants on the mechanistic association of T2DM with AD. In a recent GWAS study on AD, CLU intronic SNPs were found to be associated with the disease [4, 21, 22] . Clusterin is a transport protein and has a role in helping the clearance of amyloid-beta by transporting it through the blood-brain barrier [23] . The risk variant rs9331888 (with allele G) associated with the CLU gene increases the quantity of a CLU isoform in AD, which induces apoptosis [24] and may contribute to the accumulation of amyloid beta in AD (Fig. 5) . A study that quantified levels of clusterin isoforms showed a decrease in secreted soluble CLU in prodromal Alzheimer brain and a significant increase in intracellular CLU [25] . Furthermore, in a proteomic analysis of human hippocampal tissues from AD brains and age-matched control brains, it was confirmed that an isoform of CLU is upregulated in AD cases [26] . Moreover, AD patients have a higher expression of CLU mRNA and its concentration is positively linked to programmed cell death or apoptosis [27] . In line with these observations, expression quantitative trait loci (eQTL) analysis has shown that CLU is overexpressed in AD [28] . It is possibly linked to fibrillar amyloid-beta and apoptotic mechanisms in neurodegenerative diseases [29] . One of the SNPs (rs1532278) in the CLU gene is also associated to T2DM in GWAS analyses of diabetes patients; the amount of CLU is also significantly increased in the serum of T2DM patients, which is correlating with blood glucose levels [29] . It has been hypothesized that this SNP is linked to T2DM through insulin resistance and impairment of insulin secretion.
Similarly, genetic variants of STK11 have been linked to T2DM and also to AD in GWAS studies [39, 40] . In mouse models, the deletion of this gene is linked to the inhibition of axon branching [41] . According to GWAS studies, two intronic SNPs in the STK11 gene are associated with AD [39] . Moreover, two intronic SNPs of STK11 are also associated with T2DM. The expression of STK11 in liver seems to be required to lower blood glucose and its deficiency upregulates gluconeogenesis. Additionally, targeted STK11 deletion in liver leads to hyperglycemia [42] (Fig. 6) . Furthermore, mouse models lacking S6K1 (C57BL/6J) display enhanced insulin sensitivity [7] . The dysfunction of STK11 gene may also contribute to the accumulation of amyloid beta via the overactivation of mTOR and inhibition of autophagy. Gene expression studies show that STK11 is downregulated in AD [43] . Finally, the relevance of the regulatory and causal circuitry outlined here is underpinned by the activity of an antidiabetic drug known as metformin, which is used to activate AMPK (Adenosine monophosphate-activated protein kinase) phosphorylation and probably may repress and delay the appearance of AD pathology [44] .
Discussion
There is an unmet need for strategies to model and identify potential disease-initiating events/mechanisms in the absence of both sufficient data (which makes data-driven approaches impossible) and models for early Neurodegenerative disease (NDD) initiation (which makes a simple cause-effect analysis very difficult). We believe that complex, idiopathic diseases cannot be addressed by the established routes of molecular biology experimentation alone, as neurodegeneration works in the context of an entire organ and the pathology can only be studied in the organ context. Model-driven approaches are a way to capture the collective knowledge about disease processes and allow for a comparison at systems level.
The results of this study demonstrate that encoding relevant knowledge into causal relationship models confers enhanced interpretation power that is well-suited for hypothesis generation. BEL models of APP processing represent a broad coverage of the molecular knowledge on the pathological events underlying AD while preserving sensitivity (by inclusion of various biological pathways linked to the core pathology), specificity (by inclusion of species-and disease-specific information), and context (by inclusion of almost all types of biological Fig. 4 . Comorbidity association of Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) by genetic variants of clusterin (CLU) and serine/threonine kinase 11 (STK11) genes: In the normal state (green color edges), insulin protein binds to its receptor insulin receptor and this binding event activates INSR through phosphorylation [30] . The activated INSR binds to insulin-like growth factor 1 (IGF1) and activates insulin receptor substrate 1 (IRS1) [31] . Activated IRS1 activates the phosphoinositol signaling system which activates protein kinase B (AKT) signaling and controls glycogenesis. Activated INSR binding to IGF1 also activates Src homology 2 domain containing protein (SHC) and thereby activates the MAPK signaling pathway [32] . In the disease state (red color edges), CLU promotes neuron apoptosis [27] . Amyloid beta peptides bind to INSR, effectively preventing activation of INSR by insulin. As a consequence, through inactivation of the phosphoinositol signaling system, AKT signaling and mitogen-activated protein kinase (MAPK) signaling pathways, binding of APP peptides suppresses the insulin signaling pathway [33] . The CLU single nucleotide polymorphisms (SNPs) are associated with an increased production of amyloid beta peptides and the CLU variants increase the risk of T2DM by primarily inducing the insulin resistance and secondly by decreasing the production of insulin [34] . In the case of insulin resistance, the amount of INS is increased due to its accumulation in the blood [35] . Normally under the condition of energy stress, STK11 activates adenosine monophosphate-activated protein kinase (AMPK) by phosphorylation and AMPK activation decreases Mechanistic target of rapamycin serine/threonine kinase (mTOR) signaling activity, thereby helping degradation of b-amyloid. In T2DM, the SNP rs8111699, which maps to the enhancer region of the STK11 gene, is influencing insulin sensitivity [35] . The other SNP (rs741765) is located in the insulator region, which may block the interaction between the enhancer and promoter of the gene, resulting in downregulation of the STK11 gene [36] . Deficiency and dysfunction of STK11 inhibits the AMPK phosphorylation, thereby reducing the activity of AMPK [37] , which hyper-activates mTOR signaling in AD [38] . Moreover, in T2DM, hyperactivation of mTOR signaling inhibits IRS1 via activation of S6K1 and the IRS1 inhibition leads to insulin resistance (linking the STK11 causal graph to the CLU graph), which leads to increase in INS and glucose in blood. The black colored arrows (up and down) indicate over-or underexpression of the nodes in diseased state; while dotted arrows are inferring the possible effect of genetic variants. entities). Our approach overcomes the general problem of missing values, low reproducibility, and static representation with microarray gene expression data so that differentially expressed genes detected for the same disease are often highly inconsistent and may even fail to include genes representing key causal mechanisms [45] . For instance, the functional role of neurotrophin signaling pathway in pathology of AD could be completely ignored Fig. 5 . Evidence-based interpretation of CLU genetic variation effect: The flowchart shows the major evidences from the biological expression language (BEL)-Model that support the mechanistic interpretation of genetic variants (single nucleotide polymorphisms) of clusterin (CLU) and links these mechanisms with disease etiology of late-onset Alzheimer's disease (LOAD) and type-2-diabetes T2DM). In diseased state, CLU is inducing the increased production of amyloid beta peptides, which is binding to insulin receptor (INSR) and inhibits the insulin-signaling pathway. Moreover, CLU is associated with an increasing risk for T2DM primarily by inducing insulin resistance and secondarily by decreasing insulin secretion. It is also increasing neuron apoptosis in diseased state. if only gene expression values for BDNF, NGF, NTRK2, and NGRF were considered. In contrast, the power to detect this mechanism was remarkably increased when knowledge-based BEL models were used as the integrative platform for expression data.
We are of course aware of the fact that differences between the two models we generated could either reflect true pathomechanisms that differentiate the healthy and the diseased state, or-in the most trivial case-could reflect differences in the research published so far on a certain biology. We therefore emphasize that the differential model analysis is a way to generate hypotheses on possible pathomechanisms, but does not provide any proof for their true existence. Additional, independent evidence (e.g. SNP data that support the notion of an important, putative disease mechanism) and classical model validation strategies using independent data sets (e.g. RNAseq data) will help us to rapidly identify those hypotheses that merit an in-depth analysis, including experimental validation in appropriate experimental systems.
Our differential analysis of normal and disease states in AD and the additional supporting information provided evidence for the key role of amyloid-beta in switching the neurotrophin signaling pathway between cell survival and cell death. Retrospectively, we found an elegant study by Matrone et al. (2009) , which lends empirical support to the role of amyloid-beta in switching from prosurvival to proapoptotic activity of the neurotrophin pathway [46] . Consistent with these results and as preclinical support for the previously mentioned hypothesis, the administration of small molecule BDNF mimetics or injection of NGF to mice models of AD has been clearly shown to result in rescue from cell death and the promotion of neuronal survival [47] .
Enriched context of the APP BEL-based models with SNP data leveraged the interpretation power and allowed for linking causal effects of genetic variants to downstream molecular pathways and biological phenotypes, as exemplified for insulin resistance under AD conditions. Indeed, encoding SNPs in BEL models allows for linking SNP-associated effects to a larger functional context including biological pathways. On one hand, for most of known and statistically significant SNPs in AD GWAS results including CLU, the mode of action is not well understood but the presented BEL model in this study explains how intronic variants of CLU may increase the risk of AD through insulin resistance and increasing prevalence of T2DM. On the other hand, rare regulatory variants such as on STK11, which reside on noncoding regions of genes and are difficult to detect, have been shown to be causal for several monogenic diseases (e.g. beta-thalassemia) or modifier (e.g. sickle cell anemia) [48] but their mechanism of action is unclear. Our mechanistic models provide chains of argumentation for the causal effects of such rare regulatory variants mediated by increased levels of amyloid-beta.
It is noteworthy that BEL models go far beyond mere representation of genetic information by including downstream molecular entities and biological processes and pathways. However, BEL lacks a temporal dimension; the language has not been designed to capture kinetic information. Our future strategy to deal with the temporal dimension of Alzheimer is, to generate models representing the staging of Alzheimer by capturing the knowledge available for different stages. A first step toward stagespecific identification of biomarker candidates has already been made [49] .
We envision that the application of the (qualitative) knowledge-based model provided in this study to mechanism-identification can support target identification in drug discovery and can be further enhanced by the inclusion of quantitative data. This potential has been already shown using gene expression alterations between responders and nonresponders to infliximab therapy in ulcerative colitis patients where a quantitative causal (BEL) network analysis led to the identification of a set of stratifying genes which were confirmed by their correlation with the Mayo score, a score used to diagnose patients with active ulcerative colitis [50] .
Conclusion
Although there are clear benefits of this BEL-based, model-driven approach to understanding the complex mechanisms contributing to disease, there are some considerations for future enhancements to our models. First, given the pace of scientific research, the models need to be improved by regular update as more data and knowledge becomes available. Second, the current version of BEL describes biological interactions qualitatively and in cases where the same processes happen in both disease and normal tissue, quantitative information-when available in the literature-could allow a finer grained comparison of the diseased and normal state. Last, many studies on pathophysiology of neurodegenerative diseases like AD have been carried out in animal models, but it is not clear how well these findings are in agreement with humans. The computerization of such biological processes for representation, analysis, and comparison of interspecies mechanistic details will be a significant step forward in translational research. 
